31° Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

44.01 +0.09 (+0.19%)

Streaming Delayed Price Updated: 10:21 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗

February 12, 2026

Via MarketBeat

Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗

February 10, 2026

Exelixis (EXEL) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗

February 10, 2026

Via Chartmill

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

February 10, 2026

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup ↗

February 09, 2026

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗

January 26, 2026

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗

January 19, 2026

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗

January 15, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

February 02, 2026

From Exelixis, Inc.

Via Business Wire

2 Stocks That Could Soar This Year ↗

January 31, 2026

These innovative biotechs could have plenty of upside ahead.

Via The Motley Fool

Topics Intellectual Property

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

January 27, 2026

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

January 11, 2026

From Exelixis, Inc.

Via Business Wire

2 Healthcare Stocks to Buy for 2026 and Beyond ↗

January 08, 2026

These could be the next biotech giants.

Via The Motley Fool

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

January 07, 2026

From Exelixis, Inc.

Via Business Wire

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

January 06, 2026

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗

December 19, 2025

EXELIXIS INC (EXEL) combines strong fundamentals with a bullish technical setup. Its robust earnings growth, zero debt, and accelerating EPS align with a stock poised for a potential breakout.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗

December 15, 2025

Exelixis (EXEL) is a financially strong oncology biotech with high profitability, zero debt, and a low valuation relative to its earnings growth, fitting key value investing principles.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗

December 12, 2025

Exelixis (EXEL) exemplifies GARP investing with strong oncology earnings growth, a debt-free balance sheet, and a valuation discounted versus biotech peers.

Via Chartmill

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

December 12, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

December 03, 2025

From Exelixis, Inc.

Via Business Wire

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗

December 01, 2025

These drugmakers are poised to profit from their innovative engines.

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗

November 21, 2025

Discover EXELIXIS (EXEL), a value stock with strong profitability, zero debt, and solid growth, trading at an attractive discount to its industry peers.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗

November 19, 2025

Exelixis (EXEL) is a GARP stock with strong earnings growth, a reasonable valuation, and a debt-free balance sheet.

Via Chartmill

S&P 500 Surges as Congress Nears End to Protracted Government Shutdown

November 10, 2025

Washington D.C. – November 10, 2025 – Global financial markets are breathing a collective sigh of relief today as the S&P 500 index experiences a significant uplift, signaling investor optimism over...

Via MarketMinute

Topics Economy Regulatory Compliance Stocks

Global Markets Rally on Hopes for US Government Shutdown Resolution

November 10, 2025

Global financial markets are breathing a collective sigh of relief, with stock futures surging as investors cling to cautious optimism for an imminent end to the protracted United States government...

Via MarketMinute

Topics Bonds Economy Government

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

November 06, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

November 04, 2025

From Exelixis, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Exelixis, Inc. - Common Stock (NQ:EXEL)

All News about Exelixis, Inc. - Common Stock

Sections

Services